Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInvested CapitalMarket CapitalizationNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Sales

Avidity Biosciences (RNA) EBT Margin: 2019-2025

Historic EBT Margin for Avidity Biosciences (RNA) over the last 7 years, with Sep 2025 value amounting to -1,395.29%.

  • Avidity Biosciences' EBT Margin rose 203648.00% to -1,395.29% in Q3 2025 from the same period last year, while for Sep 2025 it was -2,628.53%, marking a year-over-year increase of 13844.00%. This contributed to the annual value of -2,955.44% for FY2024, which is 74178.00% down from last year.
  • Avidity Biosciences' EBT Margin amounted to -1,395.29% in Q3 2025, which was up 65.74% from -4,072.37% recorded in Q2 2025.
  • In the past 5 years, Avidity Biosciences' EBT Margin registered a high of -881.69% during Q1 2021, and its lowest value of -7,332.36% during Q1 2025.
  • In the last 3 years, Avidity Biosciences' EBT Margin had a median value of -2,751.39% in 2023 and averaged -3,094.49%.
  • Over the last 5 years, Avidity Biosciences' EBT Margin had its largest YoY gain of 203,648bps in 2025, and its largest YoY loss of 539,180bps in 2025.
  • Over the past 5 years, Avidity Biosciences' EBT Margin (Quarterly) stood at -2,078.40% in 2021, then surged by 25,634bps to -1,822.07% in 2022, then plummeted by 92,933bps to -2,751.39% in 2023, then tumbled by 69,489bps to -3,446.28% in 2024, then skyrocketed by 203,648bps to -1,395.29% in 2025.
  • Its EBT Margin was -1,395.29% in Q3 2025, compared to -4,072.37% in Q2 2025 and -7,332.36% in Q1 2025.